4.19
+7.44%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About MannKind
From its filings with the US Securities and Exchange Commission
MannKind is based in Danbury, Connecticut and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker MNKD. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $349.0m and net income of $5.9m. At that date it held total assets of $792.2m and shareholders' equity of −$51.0m.
We are a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. With deep expertise in drug-device combinations, we aim to deliver therapies designed to fit seamlessly into daily life.
We anticipate two potential milestones for our cardiometabolic business in 2026 based on regulatory submissions that we made in 2025. The FDA is currently reviewing a supplemental Biologics License Application ("sBLA") pursuant to which we are seeking approval for Afrezza in children and adolescents living with type 1 or type 2 diabetes. The sBLA has been assigned a Prescription Drug User Fee Act ("PDUFA") target action date of May 29, 2026. The FDA is also reviewing a supplemental New Drug Application ("sNDA") pursuant to which we are seeking approval for Furoscix ReadyFlow Autoinjector ("ReadyFlow Formulation"), a high-concentration formulation of furosemide that is delivered subcutaneously in under ten seconds. The sNDA has been assigned a PDUFA target action date of July 26, 2026.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 28 Jul 2004
- Employees
- 592
- Website
- mannkindcorp.com ↗
- Head office
- 1 CASPER STREET, DANBURY, CT, 06810
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. James ShannonIndependent Chairman of the Board$245,959
- Dr. Michael CastagnaChief Executive Officer, Director, since 2016$9.5m
- Mr. Christopher PrentissChief Financial Officer$3.4m
- Mr. Dominic MarascoPresident, Endocrine Business Unit
- Dr. Stuart TrossExecutive Vice President, Chief People and Workplace Officer$2.2m
- Dr. David ThomsonExecutive Vice President, General Counsel, Secretary$3.1m
- Mr. Sanjay SinghExecutive Vice President - Technical Operations$853,494
- Dr. Ajay AhujaChief Medical Officer
- Mr. Steven BinderDirector, since 2017$2.1m
- Mr. Ronald ConsiglioIndependent Director$235,959
- Dr. Michael FriedmanIndependent Director$210,959
- Ms. Jennifer GrancioIndependent Director$225,959
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 62
- Environment
- 35
- Social
- 95
- Governance
- 55
- Women in the workforce
- 42%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- MannKind Corp operates in the biopharmaceutical industry, specializing in the development and commercialization of novel therapeutic products.
- The company possesses advanced scientific and technological expertise, allowing them to innovate and create unique pharmaceutical products.
- MannKind has a successful track record in drug development, with a portfolio of approved products that cater to critical medical needs.
Weaknesses
- MannKind Corp heavily relies on partnerships for its commercialization and distribution activities, which can limit their control over the entire supply chain.
- The company faces financial challenges due to high research and development costs, impacting their ability to generate consistent profits.
- MannKind may have limited resources for marketing and promotion compared to larger pharmaceutical competitors.
Opportunities
- The increasing demand for innovative pharmaceutical products presents MannKind Corp with opportunities to expand its product portfolio and capture a larger market share.
- The company can explore international markets and partnerships to further grow its global presence and increase revenues.
- Technological advancements and medical breakthroughs provide MannKind with the chance to develop and introduce new drugs to address unmet medical needs.
Threats
- MannKind Corp operates in a highly competitive industry, facing intense competition from well-established pharmaceutical companies.
- Regulatory changes and requirements pose a threat to the company's ability to obtain necessary approvals and licenses for its products.
- The potential emergence of substitute products or alternative therapies may impact the demand for MannKind's offerings.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.